BioAtla announced results from its FDA Type B (End of Phase 2) meeting regarding the clinical development plan for ozuriftamab vedotin in oropharyngeal squamous cell carcinoma. The productive meeting confirmed regulatory expectations and supported the company’s ongoing development strategy for this condition. Ozuriftamab vedotin is a conditionally active biologic antibody-drug conjugate and this engagement underscores BioAtla’s commitment to advancing treatments for solid tumors using its proprietary CAB platform.